Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07525635 · ClinicalTrials.gov registry record · Early Phase 1
Aspirin Dosing in Pregnancy
A Early Phase 1 study, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT07525635 is a Early Phase 1 study that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT07525635, a Early Phase 1 study, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.
Interventions
- DRUG Aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-02-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07525635
The ClinicalTrials.gov registry entry for NCT07525635 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.
NCT07525635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07525635 about?
NCT07525635 is a clinical study titled "Aspirin Dosing in Pregnancy". The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype ...
What is the current status of trial NCT07525635?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2026-04-27. Estimated completion is 2028-02-20.
What interventions are being tested in trial NCT07525635?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT07525635?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.